The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kB ligand-stimulated induction of nuclear factor of activated T cells c1 - Urushibara, M; Takayanagi, H; Koga, T (Arthritis Rheum, 2004)
et al.